tirzepatide and inflammation Does help with Unveiling Tirzepatide's Therapeutic Spectrum: A
Description
The GLP1R/GIPR dual agonist NNC 00902746 (Novo Nordisk) significantly improved hemoglobin A1c (A1c) in T2DM (a reduction of 0.96% vs placebo) over a 12-week period, accompanied by a reduction in body weight
The patient who developed allodynia on tirzepatide 15 mg was successfully switched to oral semaglutide 14 mg without recurrence
You dont need to follow it perfectly you just need it to feel doable
Monday arrival at work coincides with the tail end of side effects
